MX344543B - Metodos y composiciones para prediccion de riesgo, diagnosis, prognosis y tratamiento de desordenes pulmonares. - Google Patents
Metodos y composiciones para prediccion de riesgo, diagnosis, prognosis y tratamiento de desordenes pulmonares.Info
- Publication number
- MX344543B MX344543B MX2012008730A MX2012008730A MX344543B MX 344543 B MX344543 B MX 344543B MX 2012008730 A MX2012008730 A MX 2012008730A MX 2012008730 A MX2012008730 A MX 2012008730A MX 344543 B MX344543 B MX 344543B
- Authority
- MX
- Mexico
- Prior art keywords
- prognosis
- diagnosis
- compositions
- treatment
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4725—Mucins, e.g. human intestinal mucin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
Abstract
La presente invención se refiere a diagnóstico y terapéuticos para enfermedad pulmonar, en particular, enfermedad de pulmón fibrótico. Los inventores han encontrado que un gen MUC5B de variante genética está asociado con la expresión incrementada del gen, el riesgo incrementado de desarrollar una enfermedad pulmonar, y una prognosis mejorada y supervivencia entre aquellos que desarrollan la enfermedad pulmonar.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29847310P | 2010-01-26 | 2010-01-26 | |
US29881410P | 2010-01-27 | 2010-01-27 | |
US32323810P | 2010-04-12 | 2010-04-12 | |
US32376010P | 2010-04-13 | 2010-04-13 | |
PCT/US2011/022621 WO2011094345A1 (en) | 2010-01-26 | 2011-01-26 | Methods and compositions for risk prediction, diagnosis, prognosis, and treatment of pulmonary disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2012008730A MX2012008730A (es) | 2012-12-17 |
MX344543B true MX344543B (es) | 2016-12-19 |
Family
ID=44319751
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2012008730A MX344543B (es) | 2010-01-26 | 2011-01-26 | Metodos y composiciones para prediccion de riesgo, diagnosis, prognosis y tratamiento de desordenes pulmonares. |
Country Status (10)
Country | Link |
---|---|
US (6) | US8673565B2 (es) |
EP (1) | EP2529033B1 (es) |
CA (2) | CA3101636A1 (es) |
DK (1) | DK2529033T3 (es) |
ES (1) | ES2636671T3 (es) |
HU (1) | HUE033044T2 (es) |
MX (1) | MX344543B (es) |
PL (1) | PL2529033T3 (es) |
SI (1) | SI2529033T1 (es) |
WO (1) | WO2011094345A1 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX344543B (es) | 2010-01-26 | 2016-12-19 | Nat Jewish Health | Metodos y composiciones para prediccion de riesgo, diagnosis, prognosis y tratamiento de desordenes pulmonares. |
WO2013092810A1 (en) * | 2011-12-21 | 2013-06-27 | University College Dublin, National University Of Ireland, Dublin | Methods relating to idiopathic pulmonary fibrosis (ipf) |
WO2014121180A1 (en) * | 2013-02-01 | 2014-08-07 | The University Of Chicago | Genetic variants in interstitial lung disease subjects |
CA2900073C (en) * | 2013-02-14 | 2023-09-26 | David A. Schwartz | Methods for predicting risk of interstitial pneumonia |
EP2968988A4 (en) | 2013-03-14 | 2016-11-16 | Allegro Diagnostics Corp | METHOD FOR EVALUATING A COPD STATUS |
EP2971128B1 (en) * | 2013-03-15 | 2023-03-01 | Veracyte, Inc. | Biomarkers for diagnosis of lung diseases and methods of use thereof |
JP6141160B2 (ja) | 2013-09-25 | 2017-06-07 | ソニーセミコンダクタソリューションズ株式会社 | 固体撮像素子およびその動作方法、並びに電子機器およびその動作方法 |
CN114606309A (zh) | 2014-11-05 | 2022-06-10 | 威拉赛特公司 | 使用机器学习和高维转录数据的诊断系统和方法 |
WO2016172150A1 (en) * | 2015-04-22 | 2016-10-27 | The University Of Chicago | Methods for treating idiopathic pulmonary fibrosis |
CA3068546A1 (en) | 2017-06-26 | 2019-01-03 | The Regents Of The University Of Colorado, A Body Corporate | Biomarkers for the diagnosis and treatment of fibrotic lung disease |
WO2021142245A1 (en) * | 2020-01-10 | 2021-07-15 | Translate Bio, Inc. | Compounds, pharmaceutical compositions and methods for modulating expression of muc5b in lung cells and tissues |
EP4232582A1 (en) * | 2020-10-23 | 2023-08-30 | Alnylam Pharmaceuticals, Inc. | Mucin 5b (muc5b) irna compositions and methods of use thereof |
WO2023105527A1 (en) * | 2021-12-09 | 2023-06-15 | Splisense Ltd. | Muc5-targeted antisense oligonucleotides and related methods for modulating expression of muc5ac and muc5b |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
EP0247091B1 (en) | 1985-11-01 | 1993-09-29 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US5496938A (en) | 1990-06-11 | 1996-03-05 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligands to HIV-RT and HIV-1 rev |
US5637459A (en) | 1990-06-11 | 1997-06-10 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: chimeric selex |
US5582981A (en) | 1991-08-14 | 1996-12-10 | Gilead Sciences, Inc. | Method for identifying an oligonucleotide aptamer specific for a target |
US5777085A (en) | 1991-12-20 | 1998-07-07 | Protein Design Labs, Inc. | Humanized antibodies reactive with GPIIB/IIIA |
US6210671B1 (en) | 1992-12-01 | 2001-04-03 | Protein Design Labs, Inc. | Humanized antibodies reactive with L-selectin |
US5830645A (en) | 1994-12-09 | 1998-11-03 | The Regents Of The University Of California | Comparative fluorescence hybridization to nucleic acid arrays |
EP0972078B1 (en) * | 1997-03-20 | 2005-06-01 | Affymetrix, Inc. (a California Corporation) | Iterative resequencing |
US6339075B1 (en) * | 1997-06-30 | 2002-01-15 | The University Of British Columbia | Use of dextran and other polysaccharides to improve mucus clearance |
AR013269A1 (es) | 1997-08-04 | 2000-12-13 | Scras | Producto que contiene por lo menos un rna de doble filamento combinado con por lo menos un agente anti-viral, para la utilizacion terapeutica en eltratamiento de una enfermedad viral, en especial de la hepatitis viral |
US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
AUPP249298A0 (en) | 1998-03-20 | 1998-04-23 | Ag-Gene Australia Limited | Synthetic genes and genetic constructs comprising same I |
GB9827152D0 (en) | 1998-07-03 | 1999-02-03 | Devgen Nv | Characterisation of gene function using double stranded rna inhibition |
JP2002531466A (ja) | 1998-12-01 | 2002-09-24 | プロテイン デザイン ラブス, インコーポレイテッド | γ−インターフェロンに対するヒト化抗体 |
EP1147204A1 (en) | 1999-01-28 | 2001-10-24 | Medical College Of Georgia Research Institute, Inc. | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna |
DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
CA2386270A1 (en) | 1999-10-15 | 2001-04-26 | University Of Massachusetts | Rna interference pathway genes as tools for targeted genetic interference |
GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
EP1358348A2 (en) * | 2000-05-09 | 2003-11-05 | Genetics Institute, LLC | Compositions, kits, and methods for identification, assessment, prevention, and therapy of psoriasis |
WO2002059300A2 (en) | 2000-12-28 | 2002-08-01 | J & J Research Pty Ltd | Double-stranded rna-mediated gene suppression |
US20030092019A1 (en) * | 2001-01-09 | 2003-05-15 | Millennium Pharmaceuticals, Inc. | Methods and compositions for diagnosing and treating neuropsychiatric disorders such as schizophrenia |
US20030040009A1 (en) | 2001-08-14 | 2003-02-27 | University Of Southern California | Saliva-based methods for preventing and assessing the risk of diseases |
US6818446B2 (en) * | 2001-11-21 | 2004-11-16 | The Regents Of The University Of California | Compositions and methods for the analysis of mucin gene expression and identification of drugs having the ability to inhibit mucin gene expression |
AU2002950878A0 (en) | 2002-08-20 | 2002-09-12 | Proteome Systems Intellectual Property Pty Ltd | Method for diagnosing disorders |
EP1403638A1 (en) | 2002-09-25 | 2004-03-31 | Mondobiotech SA | Molecular methods for diagnosing interstitial lung diseases |
US7300788B2 (en) * | 2002-10-08 | 2007-11-27 | Affymetrix, Inc. | Method for genotyping polymorphisms in humans |
US20070202109A1 (en) * | 2003-09-24 | 2007-08-30 | Oncotherapy Science, Inc. | Method Of Diagnosing Breast Cancer |
US20050125851A1 (en) * | 2003-12-09 | 2005-06-09 | Children's Hospital Research Foundation | Methods of diagnosis and treatment of interstitial lung disease |
JP4825956B2 (ja) | 2004-05-19 | 2011-11-30 | 財団法人ヒューマンサイエンス振興財団 | 気道粘膜炎症性疾患の罹患リスクの判定 |
US8076065B2 (en) | 2005-05-19 | 2011-12-13 | Synergenz Bioscience Limited | Methods and compositions for assessment of pulmonary function and disorders |
CA2666584A1 (en) | 2006-10-17 | 2008-04-24 | Synergenz Bioscience Limited | Methods and compositions for assessment of pulmonary function and disorders |
WO2008109773A2 (en) | 2007-03-06 | 2008-09-12 | Cornell Research Foundation, Inc. | Chronic obstructive pulmonary disease susceptibility and related compositions and methods |
US20120094842A1 (en) * | 2007-11-01 | 2012-04-19 | Peter Durie | Methods of assessing and treating pulmonary disease |
WO2009073167A2 (en) | 2007-12-03 | 2009-06-11 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Identification and diagnosis of pulmonary fibrosis using mucin genes, and related methods and compositions |
WO2009140715A1 (en) | 2008-05-21 | 2009-11-26 | Central Northern Adelaide Health Service | Diagnostic method |
WO2011009434A1 (de) | 2009-07-20 | 2011-01-27 | Sigismund Laskowski | Trageverpackung zur aufnahme von behältnissen |
MX344543B (es) | 2010-01-26 | 2016-12-19 | Nat Jewish Health | Metodos y composiciones para prediccion de riesgo, diagnosis, prognosis y tratamiento de desordenes pulmonares. |
-
2011
- 2011-01-26 MX MX2012008730A patent/MX344543B/es active IP Right Grant
- 2011-01-26 HU HUE11737602A patent/HUE033044T2/hu unknown
- 2011-01-26 EP EP11737602.0A patent/EP2529033B1/en active Active
- 2011-01-26 ES ES11737602.0T patent/ES2636671T3/es active Active
- 2011-01-26 WO PCT/US2011/022621 patent/WO2011094345A1/en active Application Filing
- 2011-01-26 PL PL11737602T patent/PL2529033T3/pl unknown
- 2011-01-26 CA CA3101636A patent/CA3101636A1/en active Pending
- 2011-01-26 SI SI201131250T patent/SI2529033T1/sl unknown
- 2011-01-26 CA CA2787994A patent/CA2787994C/en active Active
- 2011-01-26 US US13/014,589 patent/US8673565B2/en active Active
- 2011-01-26 DK DK11737602.0T patent/DK2529033T3/en active
-
2014
- 2014-02-03 US US14/171,536 patent/US20140220570A1/en not_active Abandoned
-
2016
- 2016-07-22 US US15/217,885 patent/US20170183730A1/en not_active Abandoned
-
2017
- 2017-11-02 US US15/802,281 patent/US10858707B2/en active Active
-
2020
- 2020-11-06 US US17/091,507 patent/US11649503B2/en active Active
-
2023
- 2023-04-25 US US18/306,648 patent/US20230313307A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP2529033A4 (en) | 2013-07-17 |
US20190040467A1 (en) | 2019-02-07 |
PL2529033T3 (pl) | 2017-10-31 |
HUE033044T2 (hu) | 2017-11-28 |
SI2529033T1 (sl) | 2017-08-31 |
CA2787994C (en) | 2021-01-12 |
US20170183730A1 (en) | 2017-06-29 |
EP2529033B1 (en) | 2017-05-24 |
US20140220570A1 (en) | 2014-08-07 |
DK2529033T3 (en) | 2017-08-07 |
CA3101636A1 (en) | 2011-08-04 |
ES2636671T3 (es) | 2017-10-06 |
CA2787994A1 (en) | 2011-08-04 |
US8673565B2 (en) | 2014-03-18 |
MX2012008730A (es) | 2012-12-17 |
WO2011094345A1 (en) | 2011-08-04 |
US11649503B2 (en) | 2023-05-16 |
US20230313307A1 (en) | 2023-10-05 |
US10858707B2 (en) | 2020-12-08 |
US20210198738A1 (en) | 2021-07-01 |
EP2529033A1 (en) | 2012-12-05 |
US20110217315A1 (en) | 2011-09-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2012008730A (es) | Metodos y composiciones para prediccion de riesgo, diagnosis, prognosis y tratamiento de desordenes pulmonares. | |
WO2010102195A3 (en) | Annexin a11 and associated genes as biomarkers for cancer | |
MX2013010343A (es) | Composicion y metodos para el transplante de microbiota de colon. | |
PH12016501728A1 (en) | Anti-angiogenesis therapy for the treatment of ovarian cancer | |
WO2013071119A3 (en) | Methods for treating, diagnosing and monitoring alzheimer's disease | |
WO2013182912A3 (en) | Method for the diagnosis, prognosis and treatment of lung cancer metastasis | |
TN2013000412A1 (en) | Bcma-based stratification and therapy for multiple myeloma patients | |
MX355543B (es) | Macrociclos peptidomiméticos. | |
EP2539470A4 (en) | METHODS FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF AUTOIMMUNE DISEASES | |
WO2013153458A3 (en) | Method for the prognosis and treatment of cancer metastasis | |
MX2013008367A (es) | Firmas de esxpresion genetica de cancer de colon y metodos de uso. | |
WO2012093821A3 (ko) | 초기유방암의 예후 예측용 유전자 및 이를 이용한 초기유방암의 예후예측 방법 | |
WO2012173846A3 (en) | Peptidomimetic macrocycles | |
MX2015004844A (es) | Firmas geneticas de trastornos inflamatorios que se relacionan con el higado. | |
WO2011106541A3 (en) | Diagnostic methods involving loss of heterozygosity | |
WO2017027391A3 (en) | Genetic abnormalities in plasma cell dyscrasias | |
AU2018290809A1 (en) | Biomarkers for the diagnosis and treatment of fibrotic lung disease | |
MX2020006388A (es) | Biomarcadores para el diagnostico y pronostico de trastornos ectaticos de la cornea. | |
WO2015121737A3 (en) | Transcriptomic biomarkers, method for determination thereof and use of trnascriptomic biomarkers for individual risk assessment of developing post-infraction heart failure | |
EA201490201A1 (ru) | Выявление экспрессии гена prame при раковом заболевании | |
WO2012078365A3 (en) | Biomarkers for prediction of breast cancer | |
MX343803B (es) | Complejo de ipp como marcador para tratamiento de erlotinib. | |
WO2015067710A3 (en) | Tyrp1, a natural mirna sponge, and its use in managing human melanoma aggressiveness | |
WO2010091296A3 (en) | Emx2 in cancer diagnosis and prognosis | |
WO2010144846A3 (en) | Gastrointestinal disease or disorder imaging and treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |